Successful Treatment with Intradetrusor Botulinum-A Toxin for Urethral Urinary Leakage (Catheter Bypassing) in Patients with End-Staged Multiple Sclerosis and Indwelling Suprapubic Catheters

European Urology

Volumn 50, Issue 4, 2006, Pages 806-810

  Lekka, Elvira ^a   Lee, Ling K ^a  

^a ROYAL BOLTON HOSPITAL   (United Kingdom)

Author keywords

Botulinum A toxin; Multiple sclerosis; Neurogenic detrusor overactivity; Urinary catheter bypassing

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; GENTAMICIN; METHYLENE BLUE;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLADDER WALL; CASE REPORT; CYSTOSCOPY; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INDWELLING CATHETER; INJECTION SITE; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PATIENT SATISFACTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; BOTULINUM TOXINS, TYPE A; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMUSCULAR AGENTS; REMISSION INDUCTION; URETHRA; URINARY CATHETERIZATION; URINARY INCONTINENCE;

EID: 33748471521     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.12.015     Document Type: Article

References (18)

1. Barnes D.G., Shaw P.J., Timoney A.G., and Tsokos N. Management of the neuropathic bladder by suprapubic catheterisation. Br J Urol 72 (1993) 169-172
2. Montecucco C., Schiavo G., Tugnoli V., and de Grandis D. Botulinum neurotoxins: mechanism of action and therapeutic applications. Mol Med Today 2 (1996) 418-424
3. Frenkl T.L., and Rackley R.R. Injectable neuromodulatory agents: Botulinum toxin therapy. Urol Clin N Am 32 (2005) 89-99
4. Shurch B., Stohrer M., Kramer G., Schmid D.M., Gaul G., and Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164 (2000) 692-697
5. Reitz A., Stohrer M., Kramer G., Del Popolo G., Chartier-Kastler E., Pannek J., et al. European experience of 200 cases treated with Botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510-515
6. Harper M., Popat R.B., Dasgupta R., Fowler C.J., and Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92 (2003) 325-326
7. Saito M., Tabuchi F., Otsubo K., and Miyagawa I. Treatment of overactive bladder with modified intravesical oxybutinin chloride. Neurourol Urodyn 19 (2000) 683-688
8. De Ridder D., Chandiramani V., Dasgupta P., Van Poppel H., Baert L., and Fowler C.J. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow up. J Urol 158 (1997) 2087-2092
9. Cruz F., Guimaraes M., Silva C., Rio M.E., Coimbra A., and Reis M. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J Urol 157 (1997) 585-589
10. Lazzeri M., Spinalli M., Beneforti P., Zanollo A., and Turini D. Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand J Urol Nephrol 32 (1998) 331-334
11. Giantanoni A., Di Stasi S.M., Stephen R.L., Bini V., Constanini E., and Porena M. Intravesical resiniferatoxin versus Botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomised study. J Urol 172 (2004) 240-243
12. Grosse J., Kramer G., and Stohrer M. Success of repeat detrusor injections of Botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47 (2005) 653-659
13. Molgo J., Lemeignan M., and Thesleff S. Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by Botulinum type A toxin. Muscle Nerve 10 (1987) 464-470
14. Bennet C.J., Young M.N., Adkins R.H., and Diaz F. Comparison of bladder management complication outcomes in female spinal cord injury patients. J Urol 153 (1995) 1458-1460
15. Haferkamp A., Schurch B., Reitz A., Krengel U., Grosse J., Kramer G., et al. Lack of ultrastructural detrusor changes following endoscopic injection of Botulinum toxin type A in overactive neurogenic bladder. Eur Urol 46 (2004) 784-791
16. Chao R., Mayo M.E., Bejany D.E., and Bavendam T. Bladder neck closure with continent augmentation or suprapubic catheter in patients with neurogenic bladders. J Am Paraplegia Soc 16 (1993) 18-22
17. Chartier-Kestler E.J., Mozer P., Denys P., Bitker M.O., Haertig A., and Richard F. Neurogenic bladder management and cutaneous non-continent ileal conduit. Spinal Cord 40 (2002) 443-448
18. Gauthier Jr. A.R., and Winters J.C. Incontinent ileovesicostomy in the management of neurogenic bladder dysfunction. Neurourol Urodyn 22 (2003) 142-146